Meeting
2024 ASCO Genitourinary Cancers Symposium
Final study analysis of PRINT: Prostate cancer intensive, non–cross-reactive therapy for CRPC.
Authors
Bobby Chi-Hung Liaw
Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY
Bobby Chi-Hung Liaw , Himanshu Joshi , Tianxiang Sheng , Che-Kai Tsao , Matt D. Galsky , Richard Lorne Bakst , Robert Stewart , Richard Stock , William K. Oh
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer - Advanced,Prostate Cancer - Localized
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT02903160
Citation
J Clin Oncol 42, 2024 (suppl 4; abstr 147)
DOI
10.1200/JCO.2024.42.4_suppl.147
Abstract #
147
Poster Bd #
F18
Abstract Disclosures
Similar Posters
Poster
2020 Genitourinary Cancers Symposium
PRINT: Prostate cancer intensive, non-cross reactive therapy for CRP—Early observations of efficacy.
First Author: Bobby Chi-Hung Liaw
Poster
2019 Genitourinary Cancers Symposium
PRINT: Prostate cancer intensive, non-cross reactive therapy for CRPC—Early observations of feasibility and efficacy.
First Author: Bobby Chi-Hung Liaw
Poster
2020 Genitourinary Cancers Symposium
Treatment outcomes for metastatic castrate-resistant prostate cancer (mCRPC) patients (pts) following docetaxel (D) for hormone sensitive disease.
First Author: Andrew Lachlan Schmidt
Poster
2014 Genitourinary Cancers Symposium
Duration of response to androgen-deprivation therapy (ADT) and efficacy of secondary hormone therapy, docetaxel (D), and cabazitaxel (C) in metastatic castration-resistant prostate cancer (mCRPC).
First Author: Antoine Angelergues